Comparative Effectiveness of Novel Oral Anticoagulants Versus Traditional Anticoagulants in Atrial Fibrillation Patients: A Narrative Review
NOACs vs VKAs in Atrial Fibrillation
DOI:
https://doi.org/10.61919/jhrr.v4i3.1446Keywords:
Atrial fibrillation, novel oral anticoagulants, NOACs, vitamin K antagonists, VKAs, stroke prevention, meta-analysis, anticoagulation therapy, safety profile, clinical outcomes.Abstract
Background: Atrial fibrillation (AF) increases the risk of stroke and systemic embolism, necessitating anticoagulation therapy. Traditional vitamin K antagonists (VKAs) like warfarin have limitations, prompting the use of novel oral anticoagulants (NOACs), which offer advantages like predictable dosing and fewer interactions.
Objective: To compare the effectiveness and safety of NOACs versus VKAs in AF patients.
Methods: A comprehensive literature search was conducted across PubMed, Cochrane CENTRAL, EMBASE, Web of Science, and Scopus to identify randomized controlled trials (RCTs) and observational studies published between 2014 and 2024. Data were synthesized using a random-effects model, with subgroup analyses based on patient characteristics. The primary outcomes included stroke, systemic embolism, and major bleeding.
Results: A total of 42 studies involving approximately 250,000 patients met the inclusion criteria. NOACs reduced the risk of stroke and systemic embolism by 19% (RR 0.81, 95% CI 0.75-0.87) and major bleeding by 16% (RR 0.84, 95% CI 0.79-0.90) compared to VKAs. NOACs also halved the risk of intracranial hemorrhage (RR 0.50, 95% CI 0.42-0.59).
Conclusion: NOACs offer comparable or superior efficacy in stroke prevention with a better safety profile than VKAs, supporting their broader adoption in clinical practice for AF patients.
Downloads
References
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran Versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139-1151.doi:10.1056/NEJMoa0905561.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban Versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981-992. doi: 10.1056/NEJMoa1107039.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883-891. doi: 10.1056/NEJMoa1009638.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials. Lancet. 2014;383(9921):955-962. doi: 10.1016/S0140-6736(13)62343-0.
De Caterina R, Ammentorp B, Darius H, Dignass A, Fauchier L, Ferroni P, et al. Stroke Prevention with Oral Anticoagulants in Atrial Fibrillation: Looking Forward to Non-Vitamin K Antagonist Oral Anticoagulants (NOACs). Thromb Haemost. 2020;120(5):753-768. doi: 10.1055/s-0040-1712152.
Lip GY, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018;154(5):1121-1201. doi: 10.1016/j.chest.2018.07.040.
Aggarwal R, Ruff CT, Virdone S, Perreault S, Kakkar AK, Palazzolo MG, et al. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. Circulation. 2023;148(12):936-46.
Al Rawahi MN, Al-Maqbali JS, Al Noumani J, Al Alawi AM, Essebag V. Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Moderate to Severe Mitral Stenosis: A Systematic Review. Cureus. 2023;15(1):e33222.
Barnett-Griness O, Stein N, Kotler A, Saliba W, Gronich N. Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants. Heart (British Cardiac Society). 2022;108(4):266-73.
Basu Roy P, Tejani VN, Dhillon SS, Damarlapally N, Winson T, Usman NUB, et al. Efficacy and Safety of Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. Cureus. 2023;15(10):e46385.
Çakmak T, Çakmak E, Balgetir F, Yaşar E, Karakuş Y. Do novel oral anticoagulant drugs used in patients with nonvalvular atrial fibrillation act only as anticoagulants? European review for medical and pharmacological sciences. 2023;27(7):2946-52.
Elfar S, Elzeiny SM, Ismail H, Makkeyah Y, Ibrahim M. Direct Oral Anticoagulants vs. Warfarin in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Frontiers in cardiovascular medicine. 2022;9:847286.
Jones DA, Wright P, Alizadeh MA, Fhadil S, Rathod KS, Guttmann O, et al. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. European heart journal Cardiovascular pharmacotherapy. 2021;7(5):398-404.
Memon MM, Siddiqui AA, Amin E, Shaikh FN, Khan MS, Doukky R, et al. Novel oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2022;99(7):2101-10.
Meya L, Polymeris AA, Schaedelin S, Schaub F, Altersberger VL, Traenka C, et al. Oral Anticoagulants in Atrial Fibrillation Patients With Recent Stroke Who Are Dependent on the Daily Help of Others. Stroke. 2021;52(11):3472-81.
Milling TJ, Jr., Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, et al. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation. 2023;147(13):1026-38.
Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2020;75(25):3122-35.
Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. 4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation. Journal of the American College of Cardiology. 2022;79(1):1-14.
Patel P, Patel SH, Siddegowda A, Potini BR, Miriyala V, Patel D, et al. Effectiveness of Novel Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cureus. 2024;16(5):e61374.
Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet (London, England). 2022;399(10333):1383-90.
Rowin EJ, Link MS, Maron MS, Maron BJ. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2023;148(22):1797-811.
Seiffge DJ, Cancelloni V, Räber L, Paciaroni M, Metzner A, Kirchhof P, et al. Secondary stroke prevention in people with atrial fibrillation: treatments and trials. The Lancet Neurology. 2024;23(4):404-17.
Singh R, Emmady PD. Rivaroxaban. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Prabhu Emmady declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.; 2024.
Zakrocka I, Załuska W. Anticoagulant-related nephropathy: Focus on novel agents. A review. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2022;31(2):165-73.
Zheng Y, Liu Y, Bi J, Lai W, Lin C, Zhu J, et al. Novel Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation and Hypertension: A Meta-Analysis. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2019;19(5):477-85.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Muhammad Ahsan Saeed, Muhammad Rizwan, Uswa Hasana, Uzair Saeed, Ali Hamza, Hamzah M. Alghzawi, Shah Bano, Saeedullah Asad
This work is licensed under a Creative Commons Attribution 4.0 International License.
